Member of the Association of American Physicians
His primary scientific interests are in Breast cancer, Internal medicine, Oncology, Cancer and Estrogen receptor. His Breast cancer research is multidisciplinary, incorporating elements of Gynecology and Bioinformatics. His work deals with themes such as Surgery and Pathology, which intersect with Internal medicine.
His Oncology research incorporates elements of Anastrozole, Randomized controlled trial, Oncotype DX, Biomarker and Prospective cohort study. Matthew J. Ellis interconnects Mutation, Cancer research and Exome in the investigation of issues within Cancer. As part of one scientific family, Matthew J. Ellis deals mainly with the area of Estrogen receptor, narrowing it down to issues related to the Endocrinology, and often Estrogen analog and Epidermal growth factor receptor.
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. His research in Breast cancer intersects with topics in Chemotherapy and Bioinformatics. His studies in Internal medicine integrate themes in fields like Endocrinology and Gynecology.
His Oncology study combines topics from a wide range of disciplines, such as Neoadjuvant therapy, Clinical trial, Aromatase, Metastatic breast cancer and Endocrine system. His Cancer study frequently links to adjacent areas such as Pathology. His biological study spans a wide range of topics, including Gene, Metastasis, Triple-negative breast cancer, PI3K/AKT/mTOR pathway and Estrogen receptor alpha.
Matthew J. Ellis spends much of his time researching Breast cancer, Internal medicine, Cancer research, Oncology and Cancer. His Breast cancer research incorporates themes from Chemotherapy and Endocrine system. The study incorporates disciplines such as Immune checkpoint, Proteogenomics, Proteomics, Metastasis and Estrogen receptor alpha in addition to Cancer research.
His Oncology research is multidisciplinary, incorporating perspectives in Fulvestrant, HER2 negative, Docetaxel, Exemestane and Prospective cohort study. His research investigates the link between Cancer and topics such as PI3K/AKT/mTOR pathway that cross with problems in Kinase. In his study, Kinome is strongly linked to Metastatic breast cancer, which falls under the umbrella field of Estrogen receptor.
His primary areas of study are Breast cancer, Cancer research, Proteomics, Internal medicine and Cancer. His study in Breast cancer is interdisciplinary in nature, drawing from both Immune checkpoint, Microarray analysis techniques and Chemotherapy. The various areas that Matthew J. Ellis examines in his Cancer research study include Aromatase inhibitor, Gene knockdown, Suppressor, Receptor and Metastasis.
His work focuses on many connections between Proteomics and other disciplines, such as Proteogenomics, that overlap with his field of interest in Computational biology, Endometrial cancer, Histone and Druggability. His Internal medicine study frequently draws connections between related disciplines such as Oncology. His studies deal with areas such as Mortality rate and Demography as well as Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt.
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck.
The New England Journal of Medicine (2004)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker;Michael Mullins;Maggie C.U. Cheang;Samuel Leung.
Journal of Clinical Oncology (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang;Stephen K Chia;David Voduc;Dongxia Gao.
Journal of the National Cancer Institute (2009)
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu;Cheng Fan;Daniel S Oh;JS Marron.
BMC Genomics (2006)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett.
Journal of the National Cancer Institute (2011)
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
Matthew J. Ellis;Andrew Coop;Baljit Singh;Louis Mauriac.
Journal of Clinical Oncology (2001)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding;Matthew J C Ellis;Shunqiang Li;David E. Larson.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Daniel F. Hayes;Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis.
Clinical Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: